Zhaoke Ophthalmology Ltd. AI Stock Analysis
Want to see HK:6622 full AI Analyst Report?
Zhaoke Ophthalmology Ltd. (6622) AI Stock Analysis
Zhaoke Ophthalmology Ltd.
(HKEX:6622)
The score is primarily constrained by substantial operating losses and persistent cash burn, despite a strong equity base and low leverage. Weak technical momentum and a negative P/E ratio provide additional headwinds.
Zhaoke Ophthalmology Ltd. (6622) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.15B
- Dividend Yield
- ―
- Average Volume (3M)
- 175.70K
- Price to Earnings (P/E)
- -4.9
- Beta (1Y)
- 1.81
- Revenue Growth
- 2.56%
- EPS Growth
- 20.20%
- Country
- Hong Kong
- Employees
- 285
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Zhaoke Ophthalmology Ltd. Business Overview & Revenue Model
Company Description
Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to researching, developing, and commercializing therapeutic solutions addressing significant unmet medical requirements in the People's Republic of China. The company is a...
Zhaoke Ophthalmology Ltd. Financial Statement Overview
Summary
Revenue reached $31M in 2025, but gross losses, a -653% net margin, $260M negative operating cash flow, and ongoing cash burn weigh heavily on performance. The $1.6B equity base and low debt-to-equity ratio provide important financial stability.
Income Statement
35NegativeBalance Sheet
65PositiveCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.75M | 31.15M | 69.32M | 18.75M | 0 | 0 |
| Gross Profit | -35.42M | -32.57M | 51.80M | 14.25M | 0 | 0 |
| EBITDA | -216.50M | -214.09M | -231.34M | -327.86M | -377.26M | -373.04M |
| Net Income | -213.55M | -203.57M | -237.49M | -385.04M | -407.32M | -2.13B |
Balance Sheet | ||||||
| Total Assets | 1.74B | 1.94B | 2.24B | 2.42B | 2.57B | 2.61B |
| Cash, Cash Equivalents and Short-Term Investments | 1.01B | 1.30B | 1.19B | 1.46B | 1.73B | 2.14B |
| Total Debt | 266.51M | 292.48M | 238.59M | 238.03M | 131.93M | 37.03M |
| Total Liabilities | 349.79M | 359.58M | 343.44M | 372.02M | 222.25M | 109.92M |
| Stockholders Equity | 1.39B | 1.58B | 1.90B | 2.05B | 2.35B | 2.50B |
Cash Flow | ||||||
| Free Cash Flow | -176.78M | -265.04M | -297.79M | -418.93M | -569.60M | -339.63M |
| Operating Cash Flow | -172.56M | -260.20M | -253.72M | -323.66M | -331.05M | -245.14M |
| Investing Cash Flow | -326.01M | 109.11M | -116.45M | -75.77M | -324.57M | 683.52M |
| Financing Cash Flow | -10.70M | 45.63M | -12.12M | 99.29M | 76.23M | 1.66B |
Zhaoke Ophthalmology Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6622, the sentiment is Neutral. The current price of 2.19 is above the 20-day moving average (MA) of 2.04, below the 50-day MA of 2.29, and below the 200-day MA of 2.73, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 53.93 is Neutral, neither overbought nor oversold. The STOCH value of 79.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6622.
Zhaoke Ophthalmology Ltd. Peers Comparison
Overall Rating
HK:147743Neutral- HK:662241Neutral
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6622 | Zhaoke Ophthalmology Ltd. | 2.19 | -1.29 | -37.21% | |
| HK:1477 | Ocumension Therapeutics | 4.97 | -3.59 | -41.88% |
Zhaoke Ophthalmology Ltd. Corporate Events
Zhaoke Ophthalmology’s Cyclosporine Ophthalmic Gel Receives NMPA Marketing Approval
Zhaoke Ophthalmology’s self-developed Cyclosporine Ophthalmic Gel received marketing approval from the National Medical Products Administration on 10 November 2026 for promoting tear secretion and improving ocular signs in dry-eye patients with reduc...
Zhaoke Ophthalmology Wins Australian GMP Nod for Guangzhou Plant
Zhaoke Ophthalmology has secured Good Manufacturing Practice certification from Australia’s Therapeutic Goods Administration for its manufacturing facility in Nansha, Guangzhou, China. The TGA is a member of the Pharmaceutical Inspection Co-operation...
Zhaoke Ophthalmology’s Presbyopia Drug YUVEZZI™ Clears Phase II Milestone in China
Zhaoke Ophthalmology Limited announced that its innovative presbyopia therapy, carbachol and brimonidine tartrate ophthalmic solution (YUVEZZIâ„¢), met the prespecified primary endpoint in a Phase II clinical study in Chinese patients. The multicenter,...
Zhaoke Ophthalmology Posts Higher Revenue but Sustains Heavy R&D-Driven Losses in First Half 2026
Zhaoke Ophthalmology Limited reported unaudited interim results for the six months ended June 30, 2026, showing revenue of RMB18.8 million, up from RMB15.8 million a year earlier, and gross profit rising to RMB9.7 million. Despite this top-line growt...
Zhaoke Ophthalmology Sets Board Meeting to Approve Interim Results
Zhaoke Ophthalmology Limited has scheduled a board meeting for August 28, 2026 to review and approve the group’s unaudited interim results for the six months ended June 30, 2026. The company plans to publish these interim figures afterward, a standar...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026